<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046964</url>
  </required_header>
  <id_info>
    <org_study_id>NCR191913</org_study_id>
    <nct_id>NCT05046964</nct_id>
  </id_info>
  <brief_title>The PPHgb Study: Non-Invasive Hemoglobin Measurement</brief_title>
  <official_title>Correlation of Non-invasive Hemoglobin Measurement With Bleeding During Cesarean Delivery: The PPHgb Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a prospective observational study aimed to assess the use of non-invasive&#xD;
      hemoglobin measurement in anticipating postpartum hemorrhage and predicting estimated blood&#xD;
      loss. The non-invasive hemoglobin device is the Radical-7 Pulse CO-Oximeter which is a&#xD;
      spectrophotometer manufactured by Masimo, Inc. Participants in the study will be undergoing a&#xD;
      cesarean delivery at the George Washington University Hospital and during delivery the&#xD;
      patient will wear the device on their fingertip so that hemoglobin measurements can be&#xD;
      continuously recorded. No changes from routine medical management will occur during the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a prospective, observational study aimed to predict bleeding using hemoglobin&#xD;
      trends measured non-invasively in patients undergoing elective cesarean delivery at the&#xD;
      George Washington University Hospital.&#xD;
&#xD;
      The primary outcome is trend in hemoglobin measurement, at which additional interventions are&#xD;
      required to control hemorrhage. The overall goal is to be able to determine a threshold point&#xD;
      in which a drop in the hemoglobin level indicates severe bleeding in anticipation of&#xD;
      postpartum hemorrhage. Through the observation of the continuous monitoring of hemoglobin&#xD;
      across all participants and correlating those with severe hemorrhage to the magnitude of drop&#xD;
      or time of drop, this could potentially optimize the hemorrhage protocol and might limit the&#xD;
      need for blood transfusion and decrease maternal mortality and morbidity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the critical threshold of SpHb drop during cesarean delivery</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of the time a SpHb drop occurs with the time of hemorrhagic intervention decision</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>Hemorrhagic interventions include: uterotonic drugs, surgical suturing, uterine tamponade devices, blood transfusion, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the change in SpHb from pre-delivery to post-delivery values and the reported estimated blood loss or change in laboratory blood hemoglobin values.</measure>
    <time_frame>Within 72 hours before surgery and 24 hours after surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Masimo Radical-7 Pulse CO-Oximeter</intervention_name>
    <description>The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women between the age of 18 - 50 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women age 18 - 50 years old&#xD;
&#xD;
          -  Patients scheduled for cesarean delivery at &gt;34 weeks gestation&#xD;
&#xD;
          -  Patients who failed trial of labor and require cesarean delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with spontaneous or operative vaginal delivery&#xD;
&#xD;
          -  Patients with hemoglobinopathies (qualitative defects, sickle-cell anemia) and&#xD;
             hemoglobin synthesis disorders (quantitative defects such as thalassemia)&#xD;
&#xD;
          -  Patients with peripheral vascular diseases and skin conditions that affect blood&#xD;
             vessels in the digit&#xD;
&#xD;
          -  Patients with hyperbilirubinemia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Homa Ahmadzia</last_name>
    <phone>202-741-2500</phone>
    <email>hahmadzia@mfa.gwu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The GW Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Homa Ahmadzia, MD</last_name>
      <phone>202-741-2500</phone>
      <email>hahmadzia@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Homa Ahmadzia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Homa Ahmadzia</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregate de-identified information will be disclosed for this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

